Scholar Rock (SRRK) Projected to Post Quarterly Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is expected to be announcing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Scholar Rock to post earnings of ($0.8472) per share and revenue of $0.30 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, hitting analysts’ consensus estimates of ($0.84). During the same quarter last year, the business posted ($0.98) EPS. On average, analysts expect Scholar Rock to post ($3.29) EPS for the current fiscal year and ($2.78) EPS for the next fiscal year.

Scholar Rock Trading Up 2.1%

Shares of Scholar Rock stock traded up $0.89 on Tuesday, hitting $43.80. 178,647 shares of the company’s stock traded hands, compared to its average volume of 1,448,875. The firm’s 50-day moving average price is $48.20 and its two-hundred day moving average price is $48.18. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. The stock has a market capitalization of $5.33 billion, a PE ratio of -12.68 and a beta of 0.61. Scholar Rock has a one year low of $27.07 and a one year high of $61.76.

Insider Activity

In other Scholar Rock news, Director Srinivas Akkaraju purchased 146,970 shares of the company’s stock in a transaction dated Monday, October 26th. The shares were bought at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the transaction, the director directly owned 6,380,517 shares in the company, valued at $265,365,702.03. This trade represents a 2.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

SRRK has been the topic of several analyst reports. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research note on Thursday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, October 15th. JPMorgan Chase & Co. boosted their target price on Scholar Rock from $63.00 to $70.00 and gave the stock an “overweight” rating in a research report on Monday, September 21st. Evercore reaffirmed an “outperform” rating and issued a $72.00 price target on shares of Scholar Rock in a research note on Tuesday, September 15th. Finally, UBS Group reiterated a “buy” rating on shares of Scholar Rock in a research report on Tuesday, September 15th. Four analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $67.67.

About Scholar Rock

Scholar Rock, Inc is a biotechnology company focused on developing medicines that selectively target growth factors in the transforming growth factor beta (TGF-?) superfamily. The company’s research is intended to address serious diseases in which these signaling pathways play an important role, including neuromuscular and metabolic conditions.

Scholar Rock’s lead investigational product is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that limits muscle growth.